Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Biosimilars

Research Grade Selicrelumab (HB782036)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HB782036
Species reactivityHuman
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHuman
IsotypeIgG2-kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession P25942
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate NamesCP-870, 893, RG-7876, RO-7009789, 1622140-49-1
BackgroundIscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. In a recent multicenter, randomized control trial (NCT02217410), with the primary endpoint of non-inferiority on the composite endpoint, iscalimab therapy showed non-inferiority on a composite clinical endpoint, improved renal function, reduced risk for new onset diabetes and similar safety compared with tacrolimus. The analysis presented at the ATC included patients from this study that underwent either routine biopsies or biopsies as part of a follow-up protocol. The data was reviewed and scored by a blinded pathologist using the established Banff criteria and CADI. A CADI of 1 or less was considered as 'normal renal histology'. The average CADI at final biopsy was 1.6 ±0.6 for iscalimab and 5.1 ±0.8 for tacrolimus.
Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    Detects CD40/TNFRSF5 in indirect ELISAs.

  • SDS-PAGE

    SDS-PAGE for Research Grade Selicrelumab.

References

Recommendation